Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-19 (Tisagenlecleucel) in Adult R/R B-ALL
NCT02030847Phase 2Completed
- Sponsor
- University of Pennsylvania
- Start
- Feb 2014
- Primary completion
- Apr 2018
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tisagenlecleucel in B cell acute lymphoblastic leukemia (B-ALL), sponsored by University of Pennsylvania. Primary endpoint: Overall Complete Remission Rate at 28 days. Started Feb 2014; status: completed.
02
Drugs
tisagenlecleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT02030847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02030847.